Request for approval by Dr Raymond Mullins (Clinical Immunologist / Allergist, Canberra)

for EpiPen® to be prescribed under PBS Authority, Version 1 November 2003

This form is to be completed by Prescribing Doctor. Please print off this form, complete details and fax to Dr Mullins at 02-6282 2526. Dr Mullins will attempt to contact prescribing doctor as soon as possible regarding authorisation.

Additional Information

ASCIA guidelines for EpiPen prescription (see end of this form)


Anaphylaxis Action Plans at http://www.allergy.org.au/aer/infobulletins/posters/Anaphylaxis_plan_(child)_Au.pdf

Instructions for Using EpiPen


PRESCRIBING DOCTOR DETAILS


Doctor's Name Provider no:
Address
Phone Fax
Email

 

Signed: Date



PATIENT DETAILS

Name D.O.B.

Contact Details (if indicated)

 




CLINICAL DETAILS


Date of reaction
: Location:


Suspected allergen:


Confirmation by:
Skin testing? Yes 0 No 0 RAST testing? Yes 0 No 0 Neither


Did the patient have:
Anaphylaxis? Yes 0 No 0
Generalised allergic reaction? Yes 0 No 0


Is the patient:
Asthmatic (concurrent or past)? Yes 0 No 0
Adolescent/ young adult? Yes 0 No 0
Nut allergic (peanut or other nut)? Yes 0 No 0
Stinging insect allergic (bee, wasp, jumper ant)? Yes 0 No 0
Suffering from ischaemic heart disease? Yes 0 No 0
Unable to readily access emergency medical care? Yes 0 No 0


Has the patient been given:
An Anaphylaxis Action Plan?* Yes 0 No 0
Allergen avoidance advice? Yes 0 No 0


Would you like this patient assessed by immunologist / allergist? Yes 0 No 0
If 'yes', please provide a referral letter to Dr Mullins with patient contact details



DISCLAIMER: Decisions about advising EpiPen and instructions for use remain the responsibility of the prescribing doctor. Dr Mullins's role is ONLY that of determining whether the patient's details fulfil the current criteria for PBS Authority subsidy. Patients falling outside these criteria are still able to purchase EpiPen privately.



Dr Raymond J Mullins. Provider No. 038384AJ; Prescriber No. 622032
Tel 02-6282 2689; Fax 02-6282 2526


PBS Authority EpiPen® prescription authorised: Yes 0 No 0
Assessment by immunologist/allergist recommended: Yes 0 No 0

 

Signed: Date:


 

Guidelines for EpiPen® Prescription © ASCIA 2003
These guidelines were developed by the ASCIA Anaphylaxis Working Party.
Membership of the working party and references for these guidelines are available on the
ASCIA website
www.allergy.org.au

1. RECOMMENDED
History of anaphylaxis* (unless patient is no longer considered to be at risk)

2. MAY BE RECOMMENDED
History of a generalised* allergic reaction with one or more of the following modifying factors These modifying factors should be considered when deciding whether an EpiPen is prescribed, as they are known risk factors for more severe or fatal reactions.

ß Asthma - concurrent or past history
ß Age - adolescents and young adults have a greater risk of fatal anaphylaxis.
- the majority of recorded fatal reactions to foods (~90%) occur in children over the age of 5 years.
ß Specific allergic triggers
Nut allergy (to peanuts or other nuts) -
most deaths from anaphylaxis occur from allergies to nuts. Generalised allergic reactions can be triggered by exposure to trace or small amounts of nuts, which can be difficult to avoid. Subsequent allergic reactions to nuts may be unpredictable.
Stinging insect allergy (Bees, wasps, Jumper ants) in adults.
ß Co-morbid conditions - Ischaemic heart disease.
ß Limited access to emergency medical care - in remote locations early administration of adrenaline may not be possible unless an EpiPen is available.

3. NOT NORMALLY RECOMMENDED
ß Asthma - in patients with asthma without anaphylaxis or generalised allergic reactions.
ß Elevated specific IgE only (positive RAST and/or skin test) without a history of clinical reactions.
Positive test results alone do not necessarily mean there is allergic disease. These patients may be referred to an allergy specialist for assessment of their risk of allergy and anaphylaxis. This may include further investigations such as challenge testing.
ß Family (rather than personal) history of anaphylaxis or allergy.
Whilst the risk for allergic disease is inherited, anaphylaxis is not inherited.
ß Local reactions to insect stings in adults and children.
ß Generalised skin rash (only) to bee or wasp stings in children.
Prospective follow-up studies of subsequent bee stings in children presenting with local reactions or generalised skin rash (only) show that these children are at a very low risk of experiencing anaphylaxis with subsequent stings.
ß Resolved food allergy.

EPIPEN JR vs EPIPEN PRESCRIPTION**
ß EpiPen JR and EpiPen are not usually recommended for children less than 10kg
ß EpiPen JR recommended for children between 10 and 20kg
ß EpiPen recommended for adults and children over 20kg

 

* Refer to definitions on page 2.
** These are based on expert opinion which is at variance with the approved product information.

IMPORTANT: An EpiPen must be prescribed within the context of a comprehensive ANAPHYLAXIS MANAGEMENT PLAN (see page 2).


ANAPHYLAXIS MANAGEMENT PLAN

An EpiPen should only be prescribed within the context of a comprehensive anaphylaxis management plan that includes the following;

ß REFERRAL TO AN ALLERGY SPECIALIST

ß IDENTIFICATION OF THE ANAPHYLACTIC TRIGGER(S)
This should include a comprehensive history, clinical examination, appropriate use and interpretation of allergy testing.

ß EDUCATION ON THE AVOIDANCE OF TRIGGER (S)
This is particularly important with food anaphylaxis.

ß PROVISION OF AN ANAPHYLAXIS ACTION PLAN
This should document the following;
o Name of child/adult
o Allergic triggers
o Carer contact details
o Symptoms and signs indicating when to use the EpiPen
o Instructions on how to use the EpiPen.

Anaphylaxis action plans for EpiPen use can also be located at www.allergy.org.au

ß APPROPRIATE FOLLOW-UP
Review by an allergy specialist should occur to;
o Ascertain if the correct trigger(s) have been identified
o Determine whether the allergy persists
o Provide re-education on EpiPen use
o Renew action plan
o Ensure the EpiPen has not expired.

 

DEFINITIONS

# 1 ANAPHYLAXIS
Anaphylaxis is a rapidly evolving generalised multi-system allergic reaction characterized by one or more symptoms or signs of respiratory and/or cardiovascular involvement and involvement of other systems such as the skin and/or the gastrointestinal tract. Symptoms/signs of respiratory/cardiovascular involvement are:

Respiratory:
ß Difficulty/noisy breathing
ß Swelling of tongue
ß Swelling/tightness in throat
ß Difficulty talking and/or hoarse voice
ß Wheeze or persistent cough
Cardiovascular:
ß Loss of consciousness
ß Collapse
ß Pale and floppy (in young children)
ß Hypotension

# 2 GENERALISED ALLERGIC REACTION
A generalised allergic reaction is a characterized by one or more symptoms or signs of skin and/or gastrointestinal tract involvement without respiratory and/or cardiovascular involvement.

Skin:
ß Generalised pruritis
ß Urticaria / Angioedema
ß Erythema
Gastrointestinal:
ß Abdominal pain
ß Vomiting
ß Loose stools